AstraZeneca enters another new development partnership

AstraZeneca announced another deal to collaborate on new drugs. The company will develop and market new cancer drugs made by Astex, a biotech based in Cambridge, England. The deal requires a $5 million upfront payment to Astex and additional milestones of up to $270 million.

The Astex deal comes on the heels of another AstraZeneca collaboration announcement that it would work with Schering to develop a new class of anti-inflammatory agents known as selective glucocorticoid receptor agents.

- read this story from The News Journal for more

PLUS: AstraZeneca taps US operations chief David Brennan to be new CEO as second-quarter profit surges by 50 percent. Story

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.